Greenwood Genetic Center, Greenwood, South Carolina.
Department of Health Sciences, University "Magna Graecia", Catanzaro, Italy.
Clin Genet. 2018 Dec;94(6):590-591. doi: 10.1111/cge.13451. Epub 2018 Oct 11.
The PNPLA3 gene maps in the 22q13 region and can have modifying effects on the phenotype of patients with Phelan-McDermid syndrome (PMS). The PNPLA3 p.I148M variant was detected in two PMS patients presenting with refractory seizures, gastrointestinal issues, and liver dysfunction. The p.I148M variant leads to macrovescicular steaosis and predisposes to liver disorders from steatohepatitis to fibrosis. Accumulation of lipid macrovescicles in the hepatocytes affects several pathways, including the metabolismof anti-epileptics, possibly leading to the lack of response to anti-epileptic treatments reported in the two cases. Screening for the p.I148M variant can identify PMS patients at higher risk for liver dyfunction and help designing personalized therapeutic protocols.
PNPLA3 基因位于 22q13 区域,可能对 Phelan-McDermid 综合征(PMS)患者的表型有修饰作用。在两名表现为难治性癫痫、胃肠道问题和肝功能障碍的 PMS 患者中检测到 PNPLA3 p.I148M 变异。p.I148M 变异导致巨泡性脂肪变性,并易患从脂肪性肝炎到纤维化的肝脏疾病。肝细胞中脂质巨泡的积累会影响包括抗癫痫药物代谢在内的多种途径,这可能导致这两种情况下报告的抗癫痫治疗反应不佳。对 p.I148M 变异的筛查可以识别出肝功能障碍风险较高的 PMS 患者,并有助于设计个性化的治疗方案。